I n the 1960s, the intracellular receptors for the steroid hormones were identified and the action of the steroid hormone was attributed to its binding with the receptor, which resulted in the activation of the genome in the cell nucleus as well as changes in the synthesis of new proteins. The genomic theory of steroid hormone action, which has been widely accepted for more than 30 years and is described in most discriminating textbooks as the sole mechanism of steroid hormone action, can satisfactorily account for most metabolic and developmental processes with slow onset and an extended time course. However, the theory met difficulties in explaining the rapid actions of steroid hormones in the body. As a complement to the classic genomic theory, a nongenomic mechanism has been proposed for the rapid action of hormonal steroids and has been widely documented (6, 13, 15, 18) . In the present review, the pleiotropic pathways for the intracellular transduction pathways of the rapid action of glucocorticoid (GC) and the possible genomic sequel to the nongenomic action of GC are discussed. If the notion of a genomic sequel to the nongenomic action can be validated by substantial data, the genomic actions of hormonal steroids may be at least twofold: a "classic" genomic action and a nongenomically induced genomic sequel.
Nongenomic action mediated via a putative membrane receptor as a plausible explanation for the rapid actions of the GC
Early observations indicated the existence of nongenomic actions of GCs. It has been observed that a rapid feedback action of GC on the pituitary occurs within 5 min after an increase of the plasma level of GC, that the rapid changes in firing activity of central neurons occurs after iontophoretic application of steroids, and that GC could rapidly inhibit the ascorbic acid uptake in the nerve terminals of the sectioned pituitary. These observations are hardly compatible with the traditional genomic theory of steroid action (5) .
We revisited the issue and first proposed a hypothesis in 1987 on the basis of the facts that 1) GC could rapidly modulate neuronal excitability by hyperpolarizing the neuronal membrane and 2) it acted on the neuron from the external surface of the plasma membrane (3, 9) (Fig. 1 ). This notion envisages a new mechanism for the rapid action of GC on neurons that is mediated by the putative membrane receptor for the steroid hormone. Because the rapid action does not involve the genome, the term "nongenomic mechanism" was introduced.
However, the rapid action of GC is not confined to its effect on neuronal excitability; it can also rapidly modulate the neuronal release of arginine vasopressin in hypothalamic slices (11) and secretion of catecholamines in adrenal chromaffin cells as well as in PC12 cell lines. Moreover, it rapidly modulates the uptake of glutamate and glycine in neurons and glia (19) . Further biochemical and morphological data substantiate the notion of a membrane receptor of GC on the neuronal plasma membrane, although the entity and identity of the putative membrane receptor for GC remains lacking in spite of the great efforts made in the last decade, including those from this laboratory (2, 5, 8) . Indeed, the situation is the same for the putative membrane receptors of all other kinds of hormonal steroids.
Multiple signal transduction pathways are involved in the rapid, nongenomic effects of GC
Because the rapid, nongenomic effects of steroid hormones are well documented, their signal transduction pathways were explored. Recent experimental results indicate that they are remarkably pleiotropic.
G protein involvement. Many observations indicated the possible involvement of G proteins in the rapid action of GC. For example, in normal cultured rat pituitary cells, GCs at a physiological concentration rapidly inhibit cAMP production and prolactin release induced by vasoactive intestinal peptide acting through specific GC receptors; GCs act rapidly in vitro to attenuate second-messenger responses to ACTH secretagogues in the rat. However, the precise mechanism underlying the process remains unknown (5) .
Binding studies also supported the involvement of G proteins in GC's rapid actions. It has been found that, in Taricha 
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2+ accumulation in cichlid fish pituitary in vitro; that dexamethasone (100 µM) could potently suppress the forskolin-stimulated cAMP efflux, ACTH secretion, and proopiomelanocortin expression; and that a pertussis toxin-sensitive GTP-binding protein might, at least partly, participate in the effect (1) . It was once suggested (5) that the protein kinase A (PKA) involvement is related to pituitary cells, but recent evidence seems to indicate that, in some cell lines, PKA is also involved in the rapid action of GC. apparently increased the membrane resistance during its hyperpolarizing effect, but when the membrane potential was manually clamped, it decreased the input resistance. The top and bottom tracings show membrane current and potential, respectively. E: in a spontaneously discharging neuron, F-BSA inhibited the discharge of the neuron while hyperpolarizing it. With the pen recorder, only excitatory postsynaptic potentials (upward deflections) and afterhyperpolarizations of the action potentials (downward deflections) were recorded, while the spikes of the action potential were too rapid to be followed. Protein kinase C pathway. It has become clear that the G protein-PKA pathway may not be the sole route for signal transduction of GC's rapid action. The G protein-protein kinase C (PKC) pathway is also involved. Electrophysiological studies demonstrated that cortisol inhibited Ca 2+ current in guinea pig hippocampal CA1 neurons via a G protein-coupled activation of protein kinase. In pertussis toxin-treated animals, cortisol inhibition was significantly diminished. Intracellular dialysis with GDPβS or with the pseudosubstrate of PKC (PKCI19-31) and PKC inhibitor bisindolylmaleide significantly diminished the cortisol inhibition of the Ca 2+ current (7) . The specific inhibitor of cAMP-dependent PKA, Rp-cAMPs, had no effect.
We -reintroduction protocol was adopted in the experiment. The result showed that the Ca 2+ influx induced by BK could be rapidly inhibited by B, but intracellular Ca 2+ release was not affected (5 ] i by B and B-BSA could also be mimicked by the PKC activator PMA and reversed by PKC inhibitors CHE and Gö-6976 (16) . The results strongly suggested that the G protein-PKC system is involved in GC's rapid action in PC12 cells.
Although pharmacological experiments clearly demonstrated the involvement of the G protein-PKC pathway in GC's rapid action, direct measurement of the PKC activity in vitro was desirable. We determined PKC activity in the membrane fractions using the SignaTECT PKC assay system from Promega. The results showed that B could activate PKC activity and the PKC inhibitor CHE could completely block the activation of PKC. The time course showed that the PKC activity was kept at a high level from 5 to 15 min of B's action. The dose-response curve was bell-shaped, with a maximal activation at 10 −9 M at 37°C but at 10 −5 M at 25°C. This finding explained why the inhibitory effect was most efficient after 5 min preincubation with B before the addition of nicotine and high K + . It has also been shown that B-BSA can directly activate the PKC activity (Fig. 2) .
In PC12 cells, cAMP levels and PKA activities were measured after treatment with B and B-BSA. It has been shown that B and B-BSA had no effect on either the resting, vasoactive intestinal peptide-stimulated, or forskolin-stimulated cAMP level and PKA activities (16) .
In cerebral cortex synaptosomes and SK-N-SH cells, GDPβS significantly blocked the augmenting effect of B on uptake of glutamate. An activator of PKA, dibutyryl cAMP, had no effect on the uptake of glutamate in synaptosomes, SK-N-SH cells, or BT-325 cells. The results indicated that PKA could not be involved in the action of GC on the uptake of glutamate. On the other hand, the involvement of PKC was uncertain (18) .
A new model of GC's rapid nongenomic action
On the basis of previous studies of the rapid, nongenomic actions of GC and the protein kinase pathways, it is clear that multiple signal transduction pathways are involved in the rapid, nongenomic effects of GC in neural cells, and a new model of GC's rapid nongenomic action has been proposed (Fig. 4A ). In the model, GC first acts on the putative membrane receptor and then via the PKA and pertussis toxin-sensitive G protein-PKC pathways to induce a variety of intracellular responses in neurons, glia, and pituitary cells. It should be emphasized that other pathways have been indicated (5) and new pathways might be disclosed. The pleiotropism in steroid's rapid action is still a big challenge for the future.
Possible genomic sequel of nongenomic action of GCs
It is well known that an elevation of cAMP levels in the cell may result in the activation of transcription through cAMP response element binding proteins. This implies the possibility of genomic activation through nongenomic activation by GCs.
However, recent data showed that the activation of mitogenactivated protein kinases (MAPKs) is also involved in the rapid action of GC. Using Western immunoblot and protein kinase activity assays, for the first time we showed that B can induce a rapid activation of extracellular signal-related kinases (ERK)-1/2, p38, and c-Jun NH 2 -terminal kinase (JNK) MAPKs in PC12 cells. The dose-response curve was bell shaped, with the maximal activation at 10 −9 M in 15 min (Fig. 3) . Activation of ERK1/2, p38, and JNK by B was apparently not mediated by the classic cytosolic steroid receptors, because B-BSA can http://physiologyonline.physiology.org/ induce the phosphorylation of these MAPKs but the antagonist of GC nuclear receptor (RU-38486) cannot block the phosphorylation of ERK1/2, p38, or JNK induced by B. Phosphorylation of ERK1/2, p38, or JNK induced by B was not affected by a tyrosine kinase inhibitor (genistein), suggesting that the pathway does not involve the tyrosine kinase activity. On the other hand, PKC activator PMA can activate and PKC inhibitor Gö-6976 can block the activation of ERK1/2, p38, and JNK induced by B. Together, these data clearly demonstrated that B might act via putative membrane receptor and rapidly activate ERK1/2, p38, and JNK through PKC in PC12 cells, which might be mediated via cRaf-1 (10). The results from immunofluorescence staining also revealed that the activated ERK1/2 was translocated from cytoplasm to nucleus in PC12 cells in 15 min (17) (Fig. 3) .
It is generally accepted that MAPK is in the downstream of receptor tyrosine kinase activation. This serine/threonine kinase, which can translocate into the cell nucleus, phosphorylates many different proteins, including transcription factors that regulate expression of important cell cycle and differentiation-specific proteins. Therefore, it is reasonable to postulate that there is a signaling pathway by which GC might affect the expression of genes that is not activated via GC receptor activation, i.e., the classic genomic pathway, but is responsive to factors acting through other pathways: PKA-cAMP response element binding protein or PKC-MAPK pathways. In short, GC can not only enhance the gene expression regulated by the nuclear receptors, i.e., the classic genomic mechanism, but can also cause a new pattern of gene expression that is the sequel of nongenomic activation, i.e., the nongenomicgenomic mechanism (Fig. 4B) .
